

Clinical Trial Protocol

Iranian Registry of Clinical Trials

14 Jun 2026

Investigating the Safety and Efficacy of Umbilical Cord Blood Serum Derived Extracellular Vesicles versus Autologous Platelet Rich Plasma and Minoxidil for Treatment of Androgenic Alopecia

Protocol summary

Study aim

Investigating the level of safety and effectiveness of extracellular vesicles derived from umbilical cord blood serum in comparison with the platelet-rich autologous plasma group and the minoxidil group in the treatment of androgenic hair loss.

Design

Clinical trial with control group, with parallel groups, double-blind, randomized, phase 1 and 2 on 30 patients, randomization: simple randomization method

Settings and conduct

Basic information, including demographic and clinical information, is collected through a questionnaire and when the patients visit the SSRC of Tehran University of Medical Sciences, and the patients are randomly divided into 3 groups of 10 people. The first group was treated with umbilical cord blood serum, the second group was treated with autologous PRP and the third group was treated with minoxidil topically, in groups 1 and 2 patients for 4 sessions with 1 month intervals. They are treated by injections. Patients will be examined with the following methods in each treatment session and 3 and 6 months after the completion of treatment.

Participants/Inclusion and exclusion criteria

Inclusion criteria: women and men with hereditary hormonal hair loss, age 18 years or older and less than 50 years, Hamilton score 2 to 5 in men and Ludwig score 1 to 3 in women, complete patient consent to participate in the project. Exclusion criteria: platelet disorders or thrombocytopenia, patients receiving anticoagulants, patients with malignancy.

Intervention groups

Patients are randomly divided into 3 groups of 10 people. The first group was treated with extra vesicles derived from umbilical cord blood serum, the second group was treated with autologous PRP, and the third group was treated with topical minoxidil.

Main outcome variables

Hair follicle density per surface unit, hair follicle thickness, hair follicle cuticle condition, hair follicle length

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20221130056672N1**

Registration date: **2023-06-21, 1402/03/31**

Registration timing: **prospective**

Last update: **2023-06-21, 1402/03/31**

Update count: **0**

Registration date

2023-06-21, 1402/03/31

Registrant information

Name

EHSAN Taghiabadi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2665 7541

Email address

etaghiabadi@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-12-23, 1402/10/02

Expected recruitment end date

2024-01-22, 1402/11/02

Actual recruitment start date

empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Investigating the Safety and Efficacy of Umbilical Cord Blood Serum Derived Extracellular Vesicles versus Autologous Platelet Rich Plasma and Minoxidil for Treatment of Androgenic Alopecia

Public title
Safety and Efficacy of Umbilical Cord Blood Serum Derived Extracellular Vesicles versus for Treatment of Androgenic Alopecia

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Women and men with hereditary hormonal hair loss Age 18 years and above and less than 50 years The rate of hair loss in patients is Hamilton score 2 to 5 in men and Ludwig score 1 to 3 in women. Complete consent of the patient to participate in the study
Exclusion criteria:

Age
From **18 years** old to **50 years** old

Gender
Both

Phase
1-2

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor

Sample size
Target sample size: **30**

Randomization (investigator's opinion)
Randomized

Randomization description
Randomization method: simple randomization. There is no stratified randomization. Randomization tool: using simple randomization method, patients who refer to Dr. Nilfroosh Zadeh's skin clinic are divided into 3 groups. In this way, out of the 30 sealed envelopes, one envelope is randomly selected for each patient. Inside each envelope is the letter A, B or C. Group A patients will be treated with extra vesicles, group B will be treated with PRP, and group C patients will be treated with minoxidil.

Blinding (investigator's opinion)
Double blinded

Blinding description
In this study, the participant, the researcher, the relevant doctor and nurse, and the evaluating doctor will be unaware of the type of treatment until the end of the study.

Placebo
Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Tehran University of Medical Sciences

Street address

Deputy Research and Technology Office, 6th Floor, Central Organization of Tehran University of Medical Sciences, Qods St, Keshavarz Blvd

City

Tehran

Province

Tehran

Postal code

1416613675

Approval date

2023-06-19, 1402/03/29

Ethics committee reference number

IR.TUMS.HORCSCT.REC.1402.018

Health conditions studied

1

Description of health condition studied

Androgenic Alopecia

ICD-10 code

L64.9

ICD-10 code description

Androgenic alopecia, unspecified

Primary outcomes

1

Description

The number of hair follicles using the Trichoscan device, the thickness of the hair follicle using the Trichoscan device

Timepoint

Before the start of the intervention, each treatment session is monthly for 4 months and also 6 months after the end of the treatment.

Method of measurement

Findings from VISIOFACE and TES-TB (low hair type with X1 lens, hair density and scalp condition with X60Triple lens, hair diameter and PORE condition with KPL X150 lens and hair shaft surface condition with X700 lens

Secondary outcomes

1

Description

Safety and Efficacy

Timepoint

At the beginning of the intervention, monthly for 4 months, every one month, after 6 months.

Method of measurement

Patient's history, examination, hair diameter, number of hair per surface unit, patient's satisfaction level.

Intervention groups

1

Description

The first group was treated with extra vesicles derived from umbilical cord blood serum with a selected concentration, the second group was treated with autologous PRP by injection, and the third group was treated with minoxidil topically.

Category

Treatment - Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Skin and Stem Cell Research Center, Tehran University of Medical Sciences

Full name of responsible person

Mohammad Ali Nilforoushzadeh

Street address

No 4 Maryam Dead End South Kamraniyeh, Andarzgo Blvd, Tehran Province, Tehran.

City

Tehran

Province

Tehran

Postal code

1937957511

Phone

+98 21 2665 7541

Email

etaghiabadi@sina.tums.ac.ir

Web page address

<https://skinstemcell.tums.ac.ir>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Mohammad Ali Nilforoushzadeh

Street address

Research and Technology Deputy, 6th floor, Quds St, Tehran University of Medical Sciences

City

Tehran

Province

Tehran

Postal code

1937957511

Phone

+98 21 2665 7438

Email

etaghiabadi@sina.tums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Ehsan Taghiabadi

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Biotechnology

Street address

No. 4, 4th floor, Maryam dead end, South Kamraniye

City

Tehran

Province

Tehran

Postal code

1937957511

Phone

+98 21 2665 7438

Email

etaghiabadi@sina.tums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Ehsan Taghiabadi
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Biotechnology
Street address
No. 4, 4th floor, Maryam dead end, South Kamraniye
City
Tehran
Province
Tehran
Postal code
1937957511
Phone
0098 2 226657438
Email
etaghiabadi@sina.tums.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Ehsan Taghiabadi
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Biotechnology
Street address
No. 4, 4th floor, Maryam dead end, South Kamraniye
City
Tehran
Province
Tehran
Postal code

1937957511
Phone
+98 21 2665 7438
Email
etaghiabadi@sina.tums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

All data can be shared after de-identifying individuals.

When the data will become available and for how long

Six months after the publication and printing of the article

To whom data/document is available

Academic researchers and experts

Under which criteria data/document could be used

In order to analyze data related to study outcomes

From where data/document is obtainable

etaghiabadi@sina.tums.ac.ir

What processes are involved for a request to access data/document

It can be submitted after review by the Research Council of the Skin and Stem Cell Research Center of Tehran University of Medical Sciences, which usually takes 2 to 3 months.

Comments